secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2026-05-21T20:13:01+00:00
Accession:  0001023024-26-000056
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma stockholders approve Amended 2022 Stock Plan, elect seven directors
------------------------------------------------------------------------------

- Approved Amended 2022 Stock Plan; authorized share reserve increased by 962,000 to 8,222,000 shares.
- All seven director nominees elected: Haughey, Lalwani, Leonard, Pera, Shanmugam, Tannenbaum, Thoma.
- Ratified Ernst & Young as independent auditor for fiscal year 2026.
- Advisory say-on-pay vote approved; future votes to be held every one year.
- Amended plan includes no-hedging policy on repricing and director compensation cap of $750k per year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000056/0001023024-26-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000056/ani-20260521.htm
  HTML page:      https://secwatch.observer/filing/0001023024-26-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer